Related Experiment Video

Updated: Jul 28, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

A cell-based system to identify and characterize the molecular mechanism of drug-metabolizing enzyme (DME) modulators

Weimin Miao1, Lianggao Hu, Mustapha Kandouz

  • 1Department of Oncology, Montreal Center for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, 3755 Cote-St-Catherine Road, Montreal, Quebec, Canada H3T 1E2.

Biochemical Pharmacology
|May 8, 2004
PubMed

Insights

This study developed a cell-based system to understand how compounds affect drug-metabolizing enzymes for cancer prevention. Researchers identified specific compounds as monofunctional inducers and found potential cross-talk between key cellular pathways.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Compounds modulating drug-metabolizing enzymes (DMEs) show cancer chemoprevention potential.
  • Understanding molecular mechanisms is crucial for effective cancer prevention strategies.

Purpose of the Study:

  • To characterize known drug-metabolizing enzyme (DME) modulators using a novel cellular system.
  • To identify structure-activity relationships and potential novel mechanisms of action for cancer chemoprevention agents.

Main Methods:

  • Utilized molecular mechanism-based assays in a cellular system.
  • Examined mRNA and protein levels of phase I and phase II drug-metabolizing enzymes.
  • Validated findings through analysis of antioxidant response element (ARE) and xenobiotic response element (XRE) pathways.

Main Results:

  • Confirmed ethoxyquin (EQ) and sulforaphane (SFP) as exclusive antioxidant response element (ARE) activators (monofunctional inducers).
  • Successfully reclassified some compounds and identified structure-activity relationships.
  • Discovered a potential novel cross-talk mechanism between ARE and xenobiotic response element (XRE) pathways.

Conclusions:

  • The developed cell-based system effectively characterizes DME modulators and aids in rational cancer chemoprevention strategy design.
  • Identified specific monofunctional inducers and elucidated structure-activity relationships.
  • Revealed a novel potential mechanism for pathway cross-talk relevant to cancer chemoprevention.

More Related Videos

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays11:17

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays

Published on: June 13, 2019

Related Concept Videos

Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
Drug Biotransformation: Overview01:28

Drug Biotransformation: Overview

Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...